新型rhNDPK-A工程菌的构建及表达产物纯化研究

目的 :为简化纯化过程 ,获得有临床研究价值的rhNDPK -A蛋白 ,构建新型rhNDPK -A基因的表达质粒 ,利用 6×His标签以Ni+ -NTA亲和层析柱纯化蛋白。方法 :将抑癌基因nm2 3-H1从质粒PBVNMH1中亚克隆于带有纯化标签的表达载体pQE4 0中。IPTG诱导表达目的蛋白。通过镍离子螯合层析柱一步纯化法纯化目的蛋白。结果 :pQE - 4 0中亚克隆的nm2 3-H1序列完全正确 ;目的蛋白在大肠杆菌M15中的表达量可达 4 9.6 % ;Ni+ -NTA亲和层析柱一步纯化后蛋白纯度为 93%。结论 :构建了带有 6×His纯化标签的新型rhNDPK -A基因表达质粒pQE -nm2 3H1,所构建质粒能高效表达目的蛋白 ,利用Ni+ -NTA亲和层析柱简便高效地纯化了表达产物。     

人血管形成素在大肠杆菌中的融合表达、纯化及活性测定

RT-PCR获取的血管形成素Angiogenin cDNA片段,克隆入融合表达载体pRSETB中,表达产物为N端融合了His6的融合蛋白,以包涵体形式存在,占菌体总蛋白的10%。用8mol/L脲溶解包涵体,利用His6与过渡态金属离子Ni⁺²高亲合力结合的性质,经Ni+2NTA亲和树脂一步法纯化,获得纯度达98%以上His6-ANG融合蛋白,Western-blot结果表明在相应分子量处有一条特异性条带。重组蛋白复性后活性测定表明,在体外可促进鸡胚绒毛尿囊膜(CAM)血管形成,并可降解tRNA。     

重组羧肽酶原B的复性方法研究*

构建的羧肽酶原B表达质粒在大肠杆菌中获得高表达。但目的蛋白是以包涵体的形式存在。为了获得活性羧肽酶B,必须对其包涵体进行变复性。首先利用稀释复性确定了羧肽酶原B复性的最佳缓冲液;在凝胶过滤复性中,研究了柱长和洗脱流速对羧肽酶原B复性效率的影响;另外对比了稀释复性、透析复性、凝胶层析复性和Ni²⁺亲合层析法等四种方法对羧肽酶原B的复性效果。结果发现,这4种方法的复性效果有以下顺序:凝胶过滤复性>稀释复性>Ni²⁺亲合层析>透析复性。     

胶质细胞源性神经营养因子受体α1基因的克隆表达及其活性研究

为了获得重组胶质细胞源性神经营养因子受体α1（glial cell line-derived neurotrophic factor receptor alpha1, GFRα1）并研究其生物学活性,从新生4天的SD大鼠海马组织中提取总RNA,通过 RT-PCR方法,扩增出GFRα1 cDNA.将GFRα1 cDNA克隆至含T7启动子的质粒pET-28a（+）中,构建表达质粒pET-GFRα1,转化大肠杆菌BL21（DE3）,获得表达菌株BLGFRα1.表达菌株经1 mmol/L IPTG诱导3～5 h后,GFRα1蛋白表达,并形成包涵体.凝胶自动扫描分析表明,GFRα1表达量占全菌总蛋白的21.5%,用Ni²⁺-NTA树脂纯化和复性后,纯度达90%以上,复性的重组GFRα1蛋白可显著介导GDNF促PC12细胞的存活和分化作用.     

重组ACTH(4-10)与GDNF融合蛋白及其生物活性研究

通过PCR方法构建了促肾上腺皮质激素4-10 (ACTH(4-10))与胶质细胞源性神经营养因子（GDNF）的融合基因,并将它重组克隆到表达载体pET-28a(+)中,构建表达质粒pET-ACTH(4-10)-GDNF,转化大肠杆菌BL21(DE3),经IPTG诱导可高效表达ACTH(4-10)-GDNF融合蛋白.用Ni²⁺-NTA树脂一步法纯化目的蛋白,纯度达85％以上.纯化和复性的ACTH(4-10)-GDNF融合蛋白能显著促进脊髓神经元存活,作用强于ACTH(4-10)及GDNF蛋白.     

人LXR-LBD原核表达载体的构建及其在E.coli中的表达

从正常中国人的肝脏组织分离总RNA,采用RT-PCR获得人的LXR-LBDcDNA,然后克隆至原核表达载体pET28a,构建高效原核表达质粒pET28a-LXR-LBD,序列分析表明正常中国人的LXR-LBDcDNA序列与GeneBank报道的序列一致.把构建的pET28a-LXR-LBD质粒转化大肠杆菌BL21(DE3),IPTG进行诱导表达,Westernblot检测表达产物,在相对分子质量35kD处有特异的蛋白表达条带,表达蛋白以可溶性和包涵体方式存在.在N末端融合6×His纯化标签的表达产物用Ni2+-NTA离子交换树脂进行纯化,纯化蛋白进行SDS-PAGE纯度分析大于90%以上.     

猪α1-干扰素的基因改造与高效原核表达

poIFNα1基因中含有大量的大肠杆菌稀有密码子,为了获得高表达,使用了大肠杆菌的偏爱密码子,人工合成了poIFN|α1成熟蛋白编码基因。在保留编码蛋白序列的同时,使其5′端A+T的含量增加到最大限度,并将其终止密码子改为TAA。将合成的poIFNα1成熟蛋白编码基因插入原核单纯表达载体pRLC中,转化大肠杆菌DH5α。实现了poIFNα1在大肠杆菌中的高效表达,表达产物以包涵体形式存在。纯化的包涵体经含DTT的6 mol/L盐酸胍的变性液溶解及含GSHGSSG的复性液复性处理,复性后的表达产物浓缩后经凝胶层析纯化,细胞病变抑制法测定表明,重组poIFNα1具有较高的抗病毒活性,约为6.4x10⁶u/mg。      

人vasorin蛋白的基因克隆、表达及纯化

目的:克隆、表达人vasorin(VASN)蛋白。方法:利用PCR方法从HepG2细胞的cDNA中扩增获得目的基因,并插入带有6×His标签的原核高效可溶性表达载体pET28a中,构建重组表达质粒pET28a-VASN,将重组表达质粒转化大肠杆菌BL21(DE3),经IPTG诱导后目的基因获得表达,对融合目的蛋白进行Ni2+金属螯合柱纯化。结果:内切酶鉴定及基因序列测定证实重组表达质粒构建成功;对目的蛋白进行了原核表达,SDS-PAGE显示相对分子质量为61×103的特异表达条带;Western印迹证实目的蛋白为VASN,且主要以包涵体形式存在;对经尿素变性的表达产物进行了亲和层析纯化,有利于以后的变性、复性过程。结论:获得了人VASN融合蛋白,为其进一步的生物学功能研究奠定了基础。     

中国三黄鸡可溶性B淋巴细胞刺激因子基因的克隆、表达和活性研究

通过逆转录-聚合酶链式反应,从中国三黄鸡脾组织细胞中扩增得到459bp的鸡可溶性B淋巴细胞刺激因子(CycsBAFF)基因片段,将其克隆入原核表达载体pET-28a,转化大肠杆菌BL21(DE3)后高效表达了带有His6标签的包涵体形式重组蛋白,通过聚丙烯酰胺凝胶电泳及免疫转印检测鉴定。表达产物经Ni2 -NTA纯化后,经透析复性得到活性目的蛋白,通过单独刺激以及与PMA共刺激体外培养的鸡法氏囊B细胞,均有明显的促法氏囊B细胞存活的效应。     

固定化镍离子亲和层析胶的制备及其性能鉴定

以Sepharose 6B为原料,在强碱性条件下用环氧氯丙烷活化,再与亚氨基二乙酸（IDA）的钠盐溶液反应,在活化好的胶颗粒表面接上很多手臂IDA;最后与硫酸镍溶液反应,使手臂IDA与Ni²⁺发生螯合反应,即得到固定化Ni²⁺亲和层析胶（Ni²⁺-IDA）.采用原子吸收法及从大肠杆菌表达产物中纯化重组人B淋巴细胞刺激因子（hBLyS）等方法检测制备胶的理化指标和纯化蛋白质的性能.结果表明用此法制得的亲和胶与相应商品胶的性能完全一致,而成本却不到商品胶的十分之一.     

N-糖酰胺酶F在大肠杆菌中的高效表达及其脱糖基化作用研究

从脑膜炎脓杆菌（Flavobacterium meningosepticum）基因组中通过PCR扩增了N-糖酰胺酶F（PNGase F）基因,经酶切后与表达载体pET28a连接,获得的重组质粒转入大肠杆菌BL21(DE3)。重组大肠杆菌经诱导表达和纯化提取后,获取大量高纯度N-糖酰胺酶F,其纯度达90%以上。试验证明,经纯化的重组N-糖酰胺酶F可以切除核糖核酸酶B、转铁蛋白和人IgG等糖蛋白上的N-糖链,具有脱糖基化作用。     

Techno-economic evaluation of an inclusion body solubilization and recombinant protein refolding process

Expression of recombinant proteins in Escherichia coli is normally accompanied by the formation of inclusion bodies (IBs). To obtain the protein product in an active (native) soluble form, the IBs must be first solubilized, and thereafter, the soluble, often denatured and reduced protein must be refolded. Several technically feasible alternatives to conduct IBs solubilization and on-column refolding have been proposed in recent years. However, rarely these on-column refolding alternatives have been evaluated from an economical point of view, questioning the feasibility of their implementation at a preparative scale. The presented study assesses the economic performance of four distinct process alternatives that include pH induced IBs solubilization and protein refolding (pH_IndSR); IBs solubilization using urea, dithiothreitol (DTT), and alkaline pH followed by batch size-exclusion protein refolding; inclusion bodies (IBs) solubilization using urea, DTT, and alkaline pH followed by simulated moving bed (SMB) size-exclusion protein refolding, and IBs solubilization using urea, DTT and alkaline pH followed by batch dilution protein refolding. The economic performance was judged on the basis of the direct fixed capital, and the production cost per unit of product (P(C)). This work shows that (1) pH_IndSR system is a relatively economical process, because of the low IBs solubilization cost; (2) substituting β-mercaptoethanol for dithiothreithol is an attractive alternative, as it significantly decreases the product cost contribution from the IBs solubilization; and (3) protein refolding by size-exclusion chromatography becomes economically attractive by changing the mode of operation of the chromatographic reactor from batch to continuous using SMB technology.     

Expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a new member of the TNF superfamily. Here, a recombinant form of the extracellular domain of the TRAIL (sTRAIL) was expressed in Escherichia coli BL21(DE3) under the control of a T7 promoter. The resulting insoluble bodies were separated from cellular debris by centrifugation and solubilized with 8 M urea. A rapid and simple on-column refolding procedure was developed. It was applied and then the refolded sTRAIL was purified by anion-exchange chromatography. The purified final product was >98% pure by SDS-PAGE stained with Coomassie brilliant blue R-250. Mass spectroscopic analysis indicated the protein to be 19.2 kDa, which equalled the theoretically expected mass. N-terminal sequencing of refolding sTRAIL showed the sequence which corresponded to the designed protein. The renatured protein displayed its immunoreactivity with the antibodies to TRAIL protein by Western blotting. The purified sTRAIL had a strong cytotoxic activity against human cervical cancer HeLa cells with ED50 about 1.5 mg/L. Circular dichroism and fluorescence spectrum analysis showed that the refolded sTRAIL had a structure similar to that of native protein with beta-sheet secondary structure. This efficient procedure of sTRAIL renaturation may be useful for the mass production of this therapeutically important protein.     

重组苦荞麦过敏蛋白TBa的原核表达及其免疫活性鉴定

TBa ［tartary buckwheat allergen］是苦荞麦中的一种主要过敏蛋白.根据长度为585 bp 的TBacDNA序列,以pET-28a为表达载体并选择合适的酶切位点合成上、下游引物,采用基因克隆技术构建重组表达载体pET-28a-TBa.进一步将重组质粒转入大肠杆菌BL21(DE3) 中进行表达.从而获得以包涵体形式存在的TBa目的蛋白.该目的蛋白经Ni ²⁺ -NTA琼脂糖柱亲和纯化及SDS-PAGE分析显示, 纯度达到95% 以上.用透析复性的方法将目的蛋白重折叠,其复性产率可达到约68%.Western印迹证实,目的蛋白N端带有6个组氨酸标签.ELISA检测表明,通过基因重组及表达获得的重组苦荞麦过敏蛋白,与天然苦荞种子中的该蛋白具有相似的免疫学活性,与荞麦过敏病人血清中的IgE有特异性的结合.     

Expression, refolding, and characterization of human soluble BAFF synthesized in Escherichia coli

The B lymphocyte stimulator (BAFF) is a novel member of the tumor necrosis factor (TNF) ligand family which is important in B lymphocyte maturation and survival. Here, a recombinant form of the extracellular domain of the BAFF (hsBAFF) was expressed in Escherichia coli BL21(DE3) under the control of a T7 promoter. The resulting insoluble bodies were separated from cellular debris by centrifugation and solubilized with 8 M urea. A rapid and simple on-column refolding procedure was developed. It was applied and then the refolded hsBAFF was purified by anion-exchange. The purified final product was >98% pure by SDS-PAGE stained with Coomassie brilliant blue R-250. Mass spectroscopic analysis indicated the protein to be 17.5 kDa, which equalled the theoretically expected mass. The N-terminal sequencing of refolding hsBAFF showed the sequence corresponded to the designed protein. The correct refolding of the recombinant protein was verified in the recovery of its secondary and tertiary structures as assessed by circular dichroism and fluorescence emission spectra. The renatured protein displayed its immunoreactivity with the antibodies to BAFF protein by Western blotting. The final purified material was biologically active in a validated induced human B lymphocyte proliferation bioassay. The expression and in vitro refolding of hsBAFF resulted in production of an active molecule in a yield of 15 mg/L flask cultivation.     

Refolding and characterization of a yeast dehydrodolichyl diphosphate synthase overexpressed in Escherichia coli.

Dehydrodolichyl diphosphate synthase (DDPPs) catalyzes the sequential condensation of isopentenyl diphosphate with farnesyl diphosphate to synthesize long-chain dehydrodolichyl diphosphate, which serves as a precursor of glycosyl carrier in glycoprotein biosynthesis in eukaryotes. To perform kinetic and structural studies of DDPPs, we have expressed yeast DDPPs using Escherichia coli as the host cell. Thioredoxin and His tag were utilized to increase the solubility of the recombinant protein and facilitate its purification using Ni-nitrilotriacetic acid (NTA) column. The protein was overexpressed in E. coli but mostly existed in pellet in the absence of detergent. The low quantity of soluble DDPPs was purified using Ni-NTA, Mono Q anion-exchange, and size-column chromatographies. The protein in the pellet was solubilized with 7 M urea and purified using Ni-NTA under denaturing condition. The protein refolding was achieved via the stepwise dialysis to remove the denaturant in the presence of 6 mM beta-mercaptoethanol. Detergent n-octyl-beta-d-glucopyranoside and Triton X-100 increased the solubility of the DDPPs so that refolding can be performed at higher protein concentration. Alternatively, on-column refolding was carried out in a single step to obtain the active protein in large quantities. beta-Mercaptoethanol and Triton were both required in this quick refolding process. The kinetic studies indicated that the soluble and refolded DDPPs have comparable activities (k(cat) = 2 x 10(-4) s(-1)). Unlike its bacterial homologue, undecaprenyl diphosphate synthase, yeast DDPPs activity was not enhanced by Triton.     

In vitro splicing of erythropoietin by the Mycobacterium tuberculosis RecA intein without substituting amino acids at the splice junctions

Protein splicing is a self-catalyzed process involving the excision of an intervening polypeptide sequence, the intein, and joining of the flanking polypeptide sequences, the extein, by a peptide bond. We have studied the in vitro splicing of erythropoietin (EPO) using a truncated form of the Mycobacterium tuberculosis RecA mini-intein in which the homing endonuclease domain was replaced with a hexahistidine sequence (His-tag). The intein was inserted adjacent to cysteine residues to assure that the spliced product had the natural amino acid sequence. When expressed in Escherichia coli, intein-containing EPO was found entirely as inclusion bodies but could be refolded in soluble form in the presence of 0.5 M arginine. Protein splicing of the refolded protein could be induced with a reducing agent such as DTT or tris(2-carboxyethyl)phosphine and led to the formation of EPO and mini-intein along with some cleavage products. Protein splicing mediated by the RecA intein requires the presence of a cysteine residue adjacent to the intein insertion site. We compared the efficiencies of protein splicing adjacent to three of the four cysteine residues of EPO (Cys29, Cys33 and Cys161) and found that insertion of intein adjacent to Cys29 allowed far more efficient protein splicing than insertion adjacent to Cys33 or Cys161. For ease of purification, our experiments involved a His-tagged EPO fusion protein and a His-tagged intein and the spliced products (25 kDa EPO and 24 kDa mini-intein) were identified by Western blotting using anti-EPO and anti-His-tag antibodies and by mass spectroscopy. The optimal splicing yield at Cys29 (40%) occurred at pH 7.0 after refolding at 4 degrees C and splicing for 18 h at 25 degrees C in the presence of 1 mM DTT.     

Highly efficient production of soluble proteins from insoluble inclusion bodies by a two-step-denaturing and refolding method

The production of recombinant proteins in a large scale is important for protein functional and structural studies, particularly by using Escherichia coli over-expression systems; however, approximate 70% of recombinant proteins are over-expressed as insoluble inclusion bodies. Here we presented an efficient method for generating soluble proteins from inclusion bodies by using two steps of denaturation and one step of refolding. We first demonstrated the advantages of this method over a conventional procedure with one denaturation step and one refolding step using three proteins with different folding properties. The refolded proteins were found to be active using in vitro tests and a bioassay. We then tested the general applicability of this method by analyzing 88 proteins from human and other organisms, all of which were expressed as inclusion bodies. We found that about 76% of these proteins were refolded with an average of >75% yield of soluble proteins. This "two-step-denaturing and refolding" (2DR) method is simple, highly efficient and generally applicable; it can be utilized to obtain active recombinant proteins for both basic research and industrial purposes.     

Efficient recovery of the functional IP10-scFv fusion protein from inclusion bodies with an on-column refolding system

A functional IP10-scFv fusion protein retaining the antibody specificity for acidic isoferritin and chemokine function was produced at high level in Esherichia coli (E. coli). IP10-scFv gene from the recombinant plasmid pc3IP104c9 was subcloned into pET28a fused to N-terminal His-tag sequence in frame and overexpressed in E. coli BL21(DE3). With an on-column refolding procedure based on Ni-chelating chromatography, the active fusion protein was recovered efficiently from inclusion bodies with a refolding yield of approximate 45% confirmed by spectrophotometer. The activity of refolded IP10-scFv was determined through sodium dodecyl sulfate-polyacrylamide gel electrophoresis, Western blotting and enzyme-linked immunosorbent assay. The results showed the fusion protein retains the specific binding activity to AIF with an affinity constant of 4.48x10(-8) M as well as the chemokine function of IP-10. The overall yield of IP10-scFv with bioactivity in E. coli flask culture was more than 40 mg/L.     

On-column refolding of recombinant human interferon-gamma inclusion bodies by expanded bed adsorption chromatography

A refolding strategy was described for on-column refolding of recombinant human interferon-gamma (rhIFN-gamma) inclusion bodies by expanded bed adsorption (EBA) chromatography. After the denatured rhIFN-gamma protein bound onto the cation exchanger of STREAMLINE SP, the refolding process was performed in expanded bed by gradually decreasing the concentration of urea in the buffer and the refolded rhIFN-gamma protein was recovered by the elution in packed bed mode. It was demonstrated that the denatured rhIFN-gamma protein could be efficiently refolded by this method with high yield. Under appropriate experimental conditions, the protein yield and specific activity of rhIFN-gamma was up to 52.7% and 8.18 x 10(6) IU/mg, respectively.